2012
Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer
McGovern SL, Qi Y, Pusztai L, Symmans WF, Buchholz TA. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Research 2012, 14: r72. PMID: 22559056, PMCID: PMC3446334, DOI: 10.1186/bcr3181.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, HormonalAutoantigensBiomarkers, TumorBreast NeoplasmsCentromere Protein ACentromere Protein BChromosomal Proteins, Non-HistoneDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansKi-67 AntigenMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalReceptors, EstrogenRNA, MessengerTamoxifenConceptsER-positive diseaseDistant relapse-free survivalSystemic therapyER-negative tumorsIndependent prognostic markerNeoadjuvant chemotherapyPrognostic markerBreast cancerChemotherapy responseKi-67Estrogen receptor-positive breast cancerReceptor-positive breast cancerER-positive breast cancerSignificant independent prognostic markerER-positive tumorsRelapse-free survivalBreast cancer patientsHigh-grade cancerSignificant independent predictorsKi-67 expressionFree survivalHazard ratioIndependent predictorsPrognostic factorsNegative tumors
2011
Gene expression profiling in breast cancer: classification, prognostication, and prediction
Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. The Lancet 2011, 378: 1812-1823. PMID: 22098854, DOI: 10.1016/s0140-6736(11)61539-0.Peer-Reviewed Original ResearchConceptsBreast cancerER-negative breast cancerGene expression profilingER-positive diseasePrognosis of patientsDistinct molecular aberrationsMolecular classification systemPotential clinical useClinical behaviorHistological featuresClinical trialsMolecular subtypesProliferation-related genesMultigene classifiersClinical practiceMolecular aberrationsExpression profilingCancerDistinct diseasesMultigene predictorsClinical useMolecular classificationDiseaseHeterogeneous groupDifferent diseases
2007
Estrogen receptor expression and efficacy of docetaxel in early breast cancer: A pooled analysis of 3,490 patients included in two randomized trials
Andre F, Broglio K, Roche H, Martin M, Penault-Lorca F, Hortobagyi G, Berry D, Pusztai L. Estrogen receptor expression and efficacy of docetaxel in early breast cancer: A pooled analysis of 3,490 patients included in two randomized trials. Journal Of Clinical Oncology 2007, 25: 537-537. DOI: 10.1200/jco.2007.25.18_suppl.537.Peer-Reviewed Original ResearchEfficacy of docetaxelRisk of deathER-positive diseaseER-negative diseaseEstrogen receptor expressionER expressionER statusPooled analysisAdjuvant chemotherapyHazard ratioRandomized trialsReceptor expressionBreast cancerAxillary node-positive breast cancerNode-positive breast cancerDocetaxel-containing regimenEarly breast cancerSubset of patientsPositive breast cancerAdjuvant treatment trialsSignificant risk reductionAdjuvant settingClinical characteristicsDocetaxel therapyOverall survival